A Comparative Study of a Curcumin, Mesalazine and a Cox-2 Inhibitors as a Therapeutic Agents for Ulcerative Colitis by Using A Swiss-Dock Model

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by immune activation, leading to persistent inflammation and tissue damage in the colon. The Janus kinase 1 (COX2) pathway plays a pivotal role in cytokine-mediated immune responses, making it a crucial therapeutic target for UC management.. This study investigates the potential of a Curcumin-Mesalazine combination as a COX2 inhibitor using SwissDock molecular docking simulations. Curcumin, a natural polyphenol derived from Curcuma longa, possesses anti-inflammatory, antioxidant, and immunomodulatory properties, while Mesalazine (%-amminosalicylic acid) is a widely used UC treatment known for its mucosal healing effects. Through docking studies, we aim to evaluate their binding affinity and interaction with COX2, assessing their potential as natural therapeutic agents. Preliminary docking results indicate strong affinities, suggesting that Curcumin-Mesalazine combination could synergistically inhibit COX2 activity. This research provides a foundation for further in vitro and in vivo studies, supporting the development of alternatives for UC treatment with potentially fewer side effects.